Bing Feng

Dr. Bing Feng


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Cell Proliferation
Verified
Journal Article
Open access
ZSZuqing Su
Zuqing Su
YLYanlin Li
Yanlin Li
ZZZihao Zhou
Zihao Zhou
BFBing Feng
Bing Feng
HCHaiming Chen
Haiming Chen
GZGuang-Juan Zheng
Guang-Juan Zheng
Colorectal cancer (CRC) is one of the most common malignant tumours and is the second leading cause of cancer‐related mortality worldwide. Despite the availability of preventative, diagnostic and treatment methods including endoscopic treatment, surgical intervention, radiotherapy, biologics, salvage therapy and immunotherapy, the mortality rate associated with CRC remains alarming. Consequently, there is a pressing need to search for medicines for the treatment of CRC. Phytomedicines have been shown to suppress the proliferation and metastasis of CRC through various mechanisms, including immune regulation, modulation of gut microbiota, targeting of stem cells, macrophage polarisation, glycolysis, ferroptosis induction, modulation of extracellular vesicles, activation of mitochondria‐induced apoptosis, inflammation reduction, oxidative stress management and intervention of autophagy. Furthermore, numerous studies have reported the anti‐cancer and anti‐metastatic effects of various phytomedicines, including curcumin, resveratrol, berberine, shikonin, dihydroartemisinin, fucoidan, luteolin, andrographolide, piperine, kaempferol, emodin, cannabidiol, tanshinone IIA and evodiamine. In this review, we sort out the effects and mechanisms of phytomedicines on CRC and outline the major phytomedicines commonly used in CRC treatment. We hope that these phytomedicines may serve as promising drugs or important lead compounds for the management of CRC.

5 August 2025 in Phytomedicine
Verified
Journal Article
Closed access
ZSZuqing Su
Zuqing Su
YLYanlin Li
Yanlin Li
ZZZihao Zhou
Zihao Zhou
LTLipeng Tang
Lipeng Tang
YZYing Zhu
Ying Zhu
GZGuang-Juan Zheng
Guang-Juan Zheng

3 July 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
CHChunxia He
Chunxia He
YLYanjing Lu
Yanjing Lu
TWTong Wang
Tong Wang
BZBowen Zhang
Bowen Zhang
ZSZuqing Su
Zuqing Su
YZYing Zhu
Ying Zhu
Xiaoji Decoction (XJD), a traditional Chinese herbal formula, has been used for decades to effectively treat non-small cell lung cancer (NSCLC), improving patients' quality of life and prolonging overall survival. Nevertheless, the molecular mechanisms responsible for the effectiveness of XJD on NSCLC remain largely unexplored. This study aims to investigate the therapeutic effects of XJD in NSCLC and to elucidate the molecular mechanisms involved. In vitro experiments were conducted by treating A549 cells with XJD at concentrations of 0, 6.25, 12.5, 25, and 50 mg/mL, and H1975 cells with XJD at concentrations of 0, 10, 20, 30, and 40 mg/mL. Ruxolitinib was used at a concentration of 10 μM. MTT assays were used to evaluate cell viability, and EdU assays were employed to measure cell proliferation. Apoptosis and cell cycle progression were analyzed by flow cytometry in vitro. The JAK1, p-STAT3, STAT3, PD-L1, BAX, Bcl-2, Cleaved Caspase-9, and Cleaved Caspase-3 were examined through Western blot analysis. In vivo experiments involved allocating mice into six groups (n = 5), including a saline control group, XJD treatment group (13.4 g/kg/day by gavage), αPD-L1 group (200 mg/mouse), Ruxolitinib group (10 mg/kg/day by gavage), XJD + Ruxolitinib group, and XJD + αPD-L1 group. Animal weight and tumor size were recorded daily for two weeks, and on day 18, the animals were sacrificed for tumor and spleen analysis. The number of macrophages present in the abdominal cavity, fresh tumors, and spleen was also measured. XJD effectively inhibited cell growth, triggered apoptosis, and induced cell cycle arrest in NSCLC cells. XJD was shown to downregulate JAK1 expression, inhibit the phosphorylation of STAT3, and reduce PD-L1 protein levels. It also decreased Bcl-2 expression while increasing the levels of BAX, Cleaved Caspase-9, and Cleaved Caspase-3, promoting cell apoptosis. Furthermore, inhibiting STAT3 phosphorylation alongside XJD treatment further amplified cell growth inhibition, induced stronger apoptosis, and more effectively arrested the cell cycle. Additionally, XJD enhanced the anti-cancer efficacy of αPD-L1, with tumor growth inhibition linked to reduced M2 macrophage infiltration and increased M1 macrophage presence. Mechanistically, combination therapies incorporating XJD with either Ruxolitinib or αPD-L1 exhibited dual therapeutic effects: 1) promotion of tumor apoptosis through enhanced caspase activation, and 2) effective suppression of the oncogenic JAK1/STAT3 signalling axis and its downstream PD-L1 expression. Our results indicate that XJD suppresses NSCLC cell growth, induces cell cycle arrest, and promotes apoptosis by inhibiting the JAK1/STAT3/PD-L1 signaling pathway. XJD has been shown to enhance the anti-cancer efficacy of αPD-L1 and exerts its anti-tumor effects by modulating macrophage polarization.